<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0011.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0013.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h93" class="calibre7"></a><a id="page_7-1" class="calibre7"></a><a href="part0002.html#rh103" class="calibre7">PITUITARY DISORDERS</a></h2>
<p class="h">H<small class="calibre30">YPOPITUITARY</small> S<small class="calibre30">YNDROMES</small> <span class="s1">(<i class="calibre22">Lancet</i> 2016;388:2403)</span></p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Primary:</b> surgery, radiation (develops after avg 4–5 y), tumors (primary or metastatic), infection, infiltration (sarcoid, hemochromatosis), autoimmune, ischemia (including Sheehan’s syndrome caused by pituitary infarction intrapartum), carotid aneurysms, cavernous sinus thrombosis, trauma, medications (eg, ipilimumab), apoplexy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Secondary</b> (hypothalamic dysfunction or stalk interruption): tumors (including craniopharyngioma), infection, infiltration, radiation, surgery, trauma</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hormonal deficiencies:</b> ACTH, TSH, FSH and LH, GH, prolactin, and ADH</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Panhypopituitarism:</b> deficiencies in multiple hormonal axes and including ADH</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mass effect:</b> headache, visual field Δs, cranial nerve palsies, galactorrhea</p>
<p class="h2a">Central adrenal insufficiency: ↓ ACTH</p>
<p class="bl"><span class="sbl">•</span> Sx similar to 1° adrenal insufficiency (see “Adrenal Disorders”) <i class="calibre3">except:</i></p>
<p class="bl1">no salt cravings or hyperkalemia (b/c aldo preserved)</p>
<p class="bl1">no hyperpigmentation (b/c ACTH/MSH is not ↑)</p>
<p class="h2a">Central hypothyroidism: ↓ TSH</p>
<p class="bl"><span class="sbl">•</span> Sx of central hypothyroidism similar to 1° (see “Thyroid Disorders”) <i class="calibre3">except</i> absence of goiter</p>
<p class="bl"><span class="sbl">•</span> Dx with free T<sub class="calibre8">4</sub> in addition to TSH, as TSH may be low or <i class="calibre3">inappropriately normal</i></p>
<p class="h2a">Hypoprolactinemia: ↓ prolactin</p>
<p class="bl"><span class="sbl">•</span> Inability to lactate</p>
<p class="h2a">Growth hormone deficiency: ↓ GH</p>
<p class="bl"><span class="sbl">•</span> ↑ chronic risk for osteoporosis, fatigue, weight gain</p>
<p class="bl"><span class="sbl">•</span> Dx with failure to ↑ GH w/ appropriate stimulus (eg, insulin tolerance test, glucagon stimulation, and macimorelin stimulation)</p>
<p class="bl"><span class="sbl">•</span> GH replacement in adults controversial <span class="s1r">(<i class="calibre3">Annals</i> 2003;35:419)</span></p>
<p class="h2a">Central hypogonadism: ↓ FSH &amp; LH</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: ↓ libido, impotence, oligomenorrhea or amenorrhea, infertility, ↓ muscle mass, osteoporosis</p>
<p class="bl"><span class="sbl">•</span> Physical exam: ↓ testicular size; loss of axillary, pubic and body hair</p>
<p class="bl"><span class="sbl">•</span> Dx with: ↓ a.m. testosterone or estradiol (also assess SHBG, esp. in obese) and ↓ or normal FSH/LH (all levels ↓ in acute illness, ∴ do not measure in hospitalized Pts)</p>
<p class="bl"><span class="sbl">•</span> Treatment: testosterone or estrogen replacement <i class="calibre3">vs.</i> correction of the underlying cause</p>
<p class="h2a">Central diabetes insipidus: ↓ ADH</p>
<p class="bl"><span class="sbl">•</span> Typically from mass lesion extrinsic to sella; pituitary tumor does not typically present w/ DI</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: <i class="calibre3">severe</i> polyuria, <i class="calibre3">mild</i> hypernatremia <span class="s1r">(<i class="calibre3">severe</i> if ↓ access to H<sub class="calibre18">2</sub>O)</span></p>
<p class="bl"><span class="sbl">•</span> Diagnostic studies: see “Sodium and Water Homeostasis”</p>
<p class="h2a"><b class="calibre4">Pituitary apoplexy</b> <span class="s">(<i class="calibre3">Endocr Rev</i> 2015;36:622)</span></p>
<p class="bl"><span class="sbl">•</span> Rapid expansion of pituitary tumor (typically adenoma) due to hemorrhage or infarction</p>
<p class="bl"><span class="sbl">•</span> Sx include excruciating headache, diploplia, hypopituitarism</p>
<p class="bl"><span class="sbl">•</span> Rx: immediate high-dose glucocorticoids; prompt surgical decompression if severe neurologic impairment or Δ MS; conservative management if mild</p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hormonal studies</b></p>
<p class="bl1"><i class="calibre3">Chronic:</i> ↓ target gland hormone + ↓ or normal trophic pituitary hormone</p>
<p class="bl1"><i class="calibre3">Acute:</i> target gland hormonal studies may be <i class="calibre3">normal</i></p>
<p class="bl1"><i class="calibre3">Partial hypopituitarism is more common than panhypopituitarism</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pituitary MRI:</b> pituitary protocol (contrast enhanced) recommended</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Replace deficient target gland hormones</b></p>
<p class="bl"><span class="sbl">•</span> Most important deficiencies to recognize and treat in inpatients are <i class="calibre3">adrenal insufficiency</i> and <i class="calibre3">hypothyroidism;</i> if both present, treat with glucocorticoids first, then replace thyroid hormone so as not to precipitate adrenal crisis</p>
<p class="h">H<small class="calibre30">YPERPITUITARY</small> S<small class="calibre30">YNDROMES</small></p>
<p class="h2a"><b class="calibre4">Pituitary tumors</b> <span class="s">(<i class="calibre3">JAMA</i> 2017;317:516)</span></p>
<p class="bl"><span class="sbl">•</span> Pathophysiology: adenoma → excess of trophic hormone (if tumor fxnal, but 30–40% not) and potentially <i class="calibre3">deficiencies</i> in other trophic hormones due to compression; cosecretion of PRL and growth hormone in 10% of prolactinomas</p>
<p class="bl"><a id="page_7-2" class="calibre1"></a><span class="sbl">•</span> Clinical manifestations: syndromes due to oversecretion of hormones (see below)</p>
<p class="bl1">± mass effect: headache, visual Δs, diplopia, cranial neuropathies</p>
<p class="bl"><span class="sbl">•</span> Workup: MRI brain pituitary protocol, hormone levels, ± visual field testing</p>
<p class="bl1">if &lt;10 mm, no mass effect, no hormonal effects, can f/up q3–6mo</p>
<p class="h2a">Hyperprolactinemia <span class="s">(<i class="calibre3">NEJM</i> 2010;362:1219; <i class="calibre3">JCEM</i> 2011;96:273)</span></p>
<p class="bl"><span class="sbl">•</span> Etiology</p>
<p class="bl1">Prolactinoma (50% of pituitary adenomas)</p>
<p class="bl1">Stalk compression due to nonprolactinoma → ↓ inhibitory dopamine → ↑ PRL (mild)</p>
<p class="bl"><span class="sbl">•</span> Physiology: PRL induces lactation and inhibits GnRH → ↓ FSH &amp; LH</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: <b class="calibre4">amenorrhea</b>, <b class="calibre4">galactorrhea</b>, <b class="calibre4">infertility</b>, ↓ libido, impotence</p>
<p class="bl"><span class="sbl">•</span> Diagnostic studies</p>
<p class="bl1">↑ <b class="calibre4">PRL</b> (✔ <i class="calibre3">fasting</i> levels), but elevated in many situations, ∴ r/o pregnancy or exogenous estrogens, hypothyroidism, dopamine agonists (eg, psych meds, antiemetics), renal failure (↓ clearance), cirrhosis, stress, ↑ carb diet. Watch for <i class="calibre3">hook effect:</i> assay artifact yielding falsely low PRL if very high serum PRL levels; retest with sample dilution.</p>
<p class="bl1"><b class="calibre4">MRI brain pituitary protocol</b></p>
<p class="bl"><span class="sbl">•</span> Treatment</p>
<p class="bl1">If asx (no HA, galactorrhea, hypogonadal sx) &amp; microadenoma (&lt;<b class="calibre4">10 mm</b>), follow w/ MRI</p>
<p class="bl1">If sx or macroadenoma (≥<b class="calibre4">10 mm</b>) options include:</p>
<p class="bl1"><i class="calibre3">Medical</i> with dopamine agonist such as cabergoline (70–100% success rate) or bromocriptine (not as well tol); side effects include N/V, orthostasis, nasal congestion</p>
<p class="bl1"><i class="calibre3">Surgical:</i> transsphenoidal surgery (main indications: failed or cannot tolerate medical Rx, GH cosecretion or neurologic sx not improving); 10–20% recurrence rate</p>
<p class="bl1"><i class="calibre3">Radiation:</i> if medical or surgical therapy have failed or are not tolerated</p>
<p class="h2a">Acromegaly <span class="s">(</span>↑ <span class="s">GH; 10% of adenomas; <i class="calibre3">NEJM</i> 2006;355:2558; <i class="calibre3">JCEM</i> 2014;99:3933)</span></p>
<p class="bl"><span class="sbl">•</span> Physiology: stimulates secretion of insulin-like growth factor 1 (IGF-1)</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: ↑ soft tissue, arthralgias, jaw enlargement, headache, carpal tunnel</p>
<p class="bl1">syndrome, macroglossia, hoarseness, sleep apnea, amenorrhea, impotence, diabetes</p>
<p class="bl1">mellitus, acanthosis/skin tags, ↑ sweating, HTN/CMP, colonic polyps</p>
<p class="bl"><span class="sbl">•</span> Diagnostic studies: <i class="calibre3">no utility in checking random GH levels because of pulsatile secretion</i></p>
<p class="bl1">↑ <b class="calibre4">IGF-1</b> (somatomedin C); ± ↑ PRL; OGTT → GH <i class="calibre3">not</i> suppressed to &lt;1 (&lt;0.3 if newer assay) ng/mL; pituitary MRI to evaluate for tumor</p>
<p class="bl"><span class="sbl">•</span> Treatment: <b class="calibre4">surgery</b>, octreotide (long- and short-acting preparations), dopamine agonists (if PRL co-secretion), pegvisomant (GH receptor antagonist), radiation</p>
<p class="bl"><span class="sbl">•</span> Prognosis: w/o Rx 2–3× ↑ mortality, risk of pituitary insufficiency, colon cancer</p>
<p class="h2a">Cushing’s disease (↑ ACTH): <span class="s2">10–15% of adenomas; see “Adrenal Disorders”</span></p>
<p class="h2a">Central hyperthyroidism (↑ TSH, ↑ α-subunit): <span class="s2">extremely rare; see “Thyroid Disorders”</span></p>
<p class="h2a">↑ FSH &amp; LH: <span class="s2">often non-fxn, may present as <i class="calibre3">hypopituitarism</i> b/c compression effects</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Multiple Endocrine Neoplasia (MEN) Syndromes</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">Type</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Main Features</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">1</b></p>
<p class="tabc">(<i class="calibre3">MENIN</i> inactiv.)</p></td>
<td class="bg0-b"><p class="tab">Parathyroid hyperplasia/adenomas → hypercalcemia (~100% penetrance)</p>
<p class="tab">Pancreatic islet cell neoplasia (gastrin, VIP, insulin, glucagon)</p>
<p class="tab">Pituitary adenomas (fxn or non-fxn)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">2A</b></p>
<p class="tabc">(<i class="calibre3">RET</i> proto- oncogene)</p></td>
<td class="bg0-b"><p class="tab">Medullary thyroid carcinoma (MTC)</p>
<p class="tab">Pheochromocytoma (~50%)</p>
<p class="tab">Parathyroid hyperplasia → hypercalcemia (15–20%)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc"><b class="calibre4">2B</b></p>
<p class="tabc">(<i class="calibre3">RET</i> proto- oncogene)</p></td>
<td class="bg"><p class="tab">Medullary thyroid carcinoma (MTC)</p>
<p class="tab">Pheochromocytoma (~50%)</p>
<p class="tab">Mucosal and gastrointestinal neuromas</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Autoimmune Polyglandular Syndromes (APS)</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">8;378:</span><span class="tfont1">11</span><span class="tfont1">32)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">Type</b></p></td>
<td class="bg0-b2"><p class="tab"><b class="calibre4">Features</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">I</b> (child onset)</p></td>
<td class="bg0-b2"><p class="tab">Mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tabc"><b class="calibre4">II</b> (adult onset)</p></td>
<td class="bg2"><p class="tab">Adrenal insufficiency, autoimmune thyroid disease, diabetes mellitus type 1</p></td>
</tr>
</table>
<h2 class="ct"><a id="h94" class="calibre7"></a><a id="page_7-3" class="calibre7"></a><a href="part0002.html#rh104" class="calibre7">THYROID DISORDERS</a></h2>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Common Diagnostic Tests in Thyroid Disorders</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Test</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Comments</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Thyroid-stimulating hormone (TSH)</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Most sensitive test</i> to detect 1° hypo- and hyperthyroidism.</p>
<p class="tab"><b class="calibre4">Used as primary screening test for thyroid disease.</b></p>
<p class="tab">↓’d by dopamine, glucocorticoids, severe illness.</p>
<p class="tab">May not be accurate in central hypothyroidism.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Free T<sub class="calibre13">4</sub> (fT<sub class="calibre13">4</sub>)</p></td>
<td class="bg0-b"><p class="tab">Unbound T<sub class="calibre13">4</sub>, not influenced by TBG. Checked in a variety of thyroid states including <i class="calibre3">hyperthyroidism</i> &amp; <i class="calibre3">central hypothyroidism</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Total T<sub class="calibre13">3</sub></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Total</i> serum concentrations of T3 (liothyronine). Useful when evaluating for <i class="calibre3">hyperthyroidism</i>.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Antithyroid peroxidase Ab (anti-TPO)</p></td>
<td class="bg"><p class="tab">Antithyroid peroxidase (TPO) seen in Hashimoto’s (high titer), painless subacute thyroiditis and Graves’ disease (low titer)</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">Lancet</i> 2001;357:619 &amp; <i class="calibre3">Thyroid</i> 2003;13:19)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre65"/>
<col class="calibre66"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Specialized Diagnostic Tests in Thyroid Disorders</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Test</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Comments</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Total T<b class="calibre4"><sub class="calibre13">4</sub></b></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Total</i> serum concentrations (∴ influenced by TBG). Checked if concern that TSH and free T4 are not accurate.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Free T<sub class="calibre13">3</sub></p></td>
<td class="bg0-b"><p class="tab">Unbound T<sub class="calibre13">3</sub>, low clinical utility</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Reverse T<sub class="calibre13">3</sub></p></td>
<td class="bg0-b"><p class="tab">Inactive, ↑’d in sick euthyroid syndrome. Rarely used clinically.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Thyroid stimulating Abs (TSI)</p></td>
<td class="bg0-b"><p class="tab">Thyroid-stimulating Ig (TSI) and thyrotropin-binding inhibitory immunoglobulin (TBII) seen in Graves’ disease. Diagnostic of Graves’ disease in high titer.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Thyroglobulin</p></td>
<td class="bg0-b"><p class="tab">↑’d in goiter, hyperthyroidism and thyroiditis</p>
<p class="tab">↓’d in factitious ingestion of thyroid hormone</p>
<p class="tabh">Tumor marker for thyroid cancer only after total thyroidectomy and radioiodine therapy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Thyroxine-binding globulin (TBG)</p></td>
<td class="bg0-b"><p class="tab">↑ TBG (∴ ↑ T<sub class="calibre13">4</sub>): estrogen (OCP, preg.), hepatitis, opioids, hereditary</p>
<p class="tabh">↓ <b class="calibre4">TBG</b> (∴ ↓ T<sub class="calibre13">4</sub>): androgens, glucocorticoids, nephritic syndrome, cirrhosis, acromegaly, antiepileptics, hereditary</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Radioactive iodine uptake (<b class="calibre4">RAIU</b>) scan</p></td>
<td class="bg"><p class="tab">Useful to differentiate causes of hyperthyroidism</p>
<p class="tab">↑ <b class="calibre4">uptake:</b> Graves’ disease, goiter or hot nodule</p>
<p class="tabh"><b class="calibre4">no uptake:</b> subacute painful (de Quervain’s) or silent thyroiditis, exogenous thyroid hormone, recent iodine load, struma ovarii or antithyroid drugs</p></td>
</tr>
</table>
<p class="capf"><b class="calibre4">Figure 7-1</b> Approach to TSH levels</p>
<p class="image"><img src="../images/00111.jpeg" alt="" class="calibre2"/></p>
<p class="h">H<small class="calibre30">YPOTHYROIDISM</small></p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> Primary (&gt;90% of cases of hypothyroidism; ↓ <b class="calibre4">free T</b><sub class="calibre8"><b class="calibre4">4</b></sub>, ↑ TSH)</p>
<p class="bl1">Goitrous: <b class="calibre4">Hashimoto’s thyroiditis</b> (after hyperthyroid phase of thyroiditis), iodine deficiency, lithium, amiodarone</p>
<p class="bl1">Nongoitrous: surgical destruction, s/p radioactive iodine or XRT, amiodarone</p>
<p class="bl"><span class="sbl">•</span> Secondary (central): ↓ free T<sub class="calibre8">4</sub>; TSH low, inappropriately nl, or slightly high (although functionally inactive due to abnormal glycosylation); due to hypothalamic or pituitary failure</p>
<p class="h2a"><a id="page_7-4" class="calibre1"></a>Hashimoto’s thyroiditis</p>
<p class="bl"><span class="sbl">•</span> Autoimmune destruction with patchy lymphocytic infiltration</p>
<p class="bl"><span class="sbl">•</span> Associated with other autoimmune disease and may be part of APS Type II</p>
<p class="bl"><span class="sbl">•</span> ⊕ antithyroid peroxidase (anti-TPO) and antithyroglobulin (anti-Tg) Abs in &gt;90%</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Annals</i> 2009;151:ITC61)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Early:</b> weakness, fatigue, arthralgias, myalgias, headache, depression, cold intolerance, weight gain, constipation, menorrhagia, dry skin, coarse brittle hair, brittle nails, carpal tunnel syndrome, delayed DTRs (“hung up” reflexes), diastolic HTN, hyperlipidemia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Late:</b> slow speech, hoarseness, loss of outer third of eyebrows, <b class="calibre4">myxedema</b> (nonpitting skin thickening due to ↑ glycosaminoglycans), periorbital puffiness, bradycardia, pleural, pericardial, &amp; peritoneal effusions, atherosclerosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Myxedema crisis:</b> hypothermia, hypotension, hypoventilation, Δ MS (including coma) hyponatremia, hypoglycemia; often precipitated by infection or major cardiopulmonary or neurologic illness <span class="s1r">(<i class="calibre3">Med Clin North Am</i> 2012;96:385)</span></p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">Lancet</i> 2017;390:1550)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ <b class="calibre4">free T<sub class="calibre8">4</sub>;</b> ↑ <b class="calibre4">TSH</b> in 1º hypothyroidism; ⊕ antithyroid Ab (TPO) in Hashimoto’s thyroiditis</p>
<p class="bl"><span class="sbl">•</span> May see hyponatremia, hypoglycemia, anemia, ↑ LDL, ↓ HDL and ↑ CK</p>
<p class="bl"><span class="sbl">•</span> Screening recommended for pregnant women</p>
<p class="h2a">Treatment of overt hypothyroidism</p>
<p class="bl"><span class="sbl">•</span> Levothyroxine (1.5–1.7 µg/kg/d), re ✔ TSH q5–6wk &amp; titrate until euthyroid (can take mos)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Lower starting dose</i> (0.3–0.5 µg/kg/d) if at risk for ischemic heart disease or elderly</p>
<p class="bl"><span class="sbl">•</span> ↑ dose typically needed if:</p>
<p class="bl1">poor GI absorption: meds that ↓ absorption (iron, calcium, cholestyramine, sucralfate, PPI), celiac disease, IBD</p>
<p class="bl1">meds that accelerate T<sub class="calibre8">4</sub> catabolism (eg, phenytoin, phenobarbital)</p>
<p class="bl1">initiation of estrogen replacement; pregnancy (~30% ↑ by wk 8): TSH goals change by trimester: 1<sup class="calibre15">st</sup> = 0.1–4.0 mIU/L, 2<sup class="calibre15">nd</sup> &amp; 3<sup class="calibre15">rd</sup> = gradual return of TSH to nonpregnant nl range <span class="s1r">(<i class="calibre3">Thyroid</i> 2017;3:315)</span></p>
<p class="h2a">Subclinical hypothyroidism <span class="s">(<i class="calibre3">NEJM</i> 2017;376:2556; <i class="calibre3">JAMA</i> 2019;322:153)</span></p>
<p class="bl"><span class="sbl">•</span> Mild ↑ TSH and <b class="calibre4">normal free T</b><sub class="calibre8"><b class="calibre4">4</b></sub> with only subtle or no sx</p>
<p class="bl"><span class="sbl">•</span> If TSH &lt;7 or ⊖ anti-TPO Ab, ~<span class="s">¹</span>∕² resolve after 2 y <span class="s1r">(<i class="calibre3">JCEM</i> 2012;97:1962)</span> if ↑ titers of antithyroid Abs, progression to overt hypothyroidism is ~4%/y</p>
<p class="bl"><span class="sbl">•</span> No clear benefit to Rx <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:2534)</span>. In practice, follow expectantly or Rx to improve mild sx or dyslipidemia. Experts often Rx if TSH &gt;10 mU/L, goiter, pregnancy or infertility.</p>
<p class="h2a"><b class="calibre4">Myxedema coma (ie, profound hypothyroidism;</b> <span class="s"><i class="calibre3">Med Clin North Am</i> 2012;96:385</span><b class="calibre4">)</b></p>
<p class="bl"><span class="sbl">•</span> Presentation: hypothermia, hypotension, hypoventilation, Δ MS (coma rare), hyponatremia, hypoglycemia; often precipitated by infxn or major cardiopulmonary or neurologic illness</p>
<p class="bl"><span class="sbl">•</span> Treatment: supportive care most important. Slow metabolism of drugs can lead to coma. Correction of hypothyroidism takes time. Load 5–8 µg/kg T<sub class="calibre8">4</sub> IV, then 50–100 µg IV qd; b/c peripheral conversion impaired, may also give 5–10 µg T<sub class="calibre8">3</sub> IV q8h if unstable w/ bradycardia and/or hypothermia (T<sub class="calibre8">3</sub> more arrhythmogenic); must give <b class="calibre4">empiric <i class="calibre3">adrenal replacement therapy</i></b> first as ↓ adrenal reserves in myxedema coma.</p>
<p class="h">H<small class="calibre30">YPERTHYROIDISM</small></p>
<p class="h2a">Etiologies <span class="s">(<i class="calibre3">Lancet</i> 2016;388:906)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Graves’ disease</b> (60–80% of thyrotoxicosis)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Thyroiditis:</b> thyrotoxic phase of subacute (granulomatous) or painless (lymphocytic)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Toxic adenomas</b> (single or multinodular goiter)</p>
<p class="bl"><span class="sbl">•</span> Extremely rare: TSH-secreting pituitary tumor or pituitary resistant to thyroid hormone (↑ TSH, ↑ free T<sub class="calibre8">4</sub>)</p>
<p class="bl"><span class="sbl">•</span> Misc: amiodarone, iodine-induced, thyrotoxicosis factitia, struma ovarii (3% of ovarian dermoid tumors and teratomas), hCG-secreting tumors (eg, choriocarcinoma), large deposits of metastatic follicular thyroid cancer</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Restlessness, sweating, tremor, moist warm skin, fine hair, tachycardia, AF, weight loss, ↑ frequency of stools, menstrual irregularities, hyperreflexia, osteoporosis, stare and lid lag (due to sympathetic overactivity)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Apathetic thyrotoxicosis:</b> seen in elderly who can present with lethargy as only sx</p>
<p class="h2a">Laboratory testing</p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">free T</b><sub class="calibre8"><b class="calibre4">4</b></sub> and <b class="calibre4">total T</b><sub class="calibre8"><b class="calibre4">3</b></sub><b class="calibre4">;</b> ↓ <b class="calibre4">TSH</b> (except in TSH-secreting tumors)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">RAIU scan</b> is very useful study to differentiate causes (see table on <a href="part0012.html#page_7-3" class="calibre1">page 7-3</a>); cannot do if recent IV contrast or amio load b/c iodine blocks uptake, so ✔ autoantibodies instead</p>
<p class="bl"><span class="sbl">•</span> Rarely need to ✔ for autoantibodies except in pregnancy (to assess risk of fetal Graves’)</p>
<p class="bl"><span class="sbl">•</span> May see hypercalciuria ± hypercalcemia, ↑ Aϕ, anemia</p>
<p class="capf"><a id="page_7-5" class="calibre1"></a><b class="calibre4">Figure 7-2</b> Workup of primary hyperthyroidism</p>
<p class="image"><img src="../images/00112.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Graves’ disease <span class="s">(<i class="calibre3">NEJM</i> 2016;375:1552)</span></p>
<p class="bl"><span class="sbl">•</span> ♀:♂ ratio is 5–10:1, most Pts between 40 and 60 y at dx</p>
<p class="bl"><span class="sbl">•</span> ⊕ <b class="calibre4">thyroid antibodies:</b> TSI or TBII (⊕ in 80%), anti-TPO, antithyroglobulin; ANA</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations in addition to those of hyperthyroidism (see above):</p>
<p class="bl1"><b class="calibre4">Goiter:</b> diffuse, nontender, w/ thyroid bruit</p>
<p class="bl1"><b class="calibre4">Ophthalmopathy</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2010;362:726)</span>: seen in 50%; up to 90% if formally tested. Periorbital edema, lid retraction, proptosis, conjunctivitis, diplopia (EOM infiltration); associated w/ smoking. Stare and lid lag seen in any type of hyperthyroidism.</p>
<p class="bl1"><b class="calibre4">Pretibial myxedema</b> (3%): infiltrative dermopathy</p>
<p class="h2a">Thyroiditis <span class="s">(<i class="calibre3">NEJM</i> 2003;348:2646; <i class="calibre3">Med Clin North Am</i> 2012;96:223)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Acute:</b> bacterial infection (very rare in U.S. except postsurgical), typically <i class="calibre3">Staph/Strep</i> spp.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Subacute:</b> transient thyrotoxicosis → transient hypothyroidism → normal thyroid fxn</p>
<p class="bl1"><b class="calibre4">Painful</b> (viral, granulomatous or de Quervain’s): fever, ↑ ESR; Rx = NSAIDs, ASA, steroids</p>
<p class="bl1"><b class="calibre4">Silent</b> (postpartum, autoimmune including Hashimoto’s, or lymphocytic): painless, ⊕ TPO Abs; if postpartum, can recur with subsequent pregnancies</p>
<p class="bl1"><b class="calibre4">Other:</b> meds (amiodarone, lithium, TKIs), palpation thyroiditis, post-radiation</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Thyroid</i> 2011;21:593)</span></p>
<p class="bl"><span class="sbl">•</span> β-blockers: control tachycardia (propranolol also ↓ T<sub class="calibre8">4</sub> → T<sub class="calibre8">3</sub> conversion)</p>
<p class="bl"><span class="sbl">•</span> Graves’ disease: either antithyroid drugs or radioactive iodine <span class="s1r">(<i class="calibre3">JAMA</i> 2015;314:2544)</span></p>
<p class="bl1"><b class="calibre4">methimazole:</b> 70% chance of recurrence after 1 y; side effects include pruritus, rash, arthralgia, fever, N/V and <i class="calibre3">agranulocytosis</i> in 0.5%. PTU: 2<sup class="calibre15">nd</sup> line (risk of hepatocellular necrosis; TID dosing; slower effect; <i class="calibre3">JCEM</i> 2007;92:2157). For both, need to ✔ LFTs, WBC, TSH at baseline and in follow-up.</p>
<p class="bl1"><b class="calibre4">radioactive iodine (RAI)</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2011;364:542)</span>: typically done as outPt; preRx w/ antithyroid drugs in selected Pts w/ CV disease or elderly to prevent ↑ thyrotoxicosis, stop 3 d before to allow RAI uptake; &gt;75% of treated Pts become hypothyroid</p>
<p class="bl1"><b class="calibre4">surgery:</b> less commonly chosen for Graves’, usually for Pts w/ obstructive goiter or ophthalmopathy</p>
<p class="bl"><span class="sbl">•</span> Ophthalmopathy: can worsen after RAI; prophylax w/ prednisone in high-risk Pts; can be Rx’d w/ radiation and/or surgical decompression of orbits <span class="s1r">(<i class="calibre3">NEJM</i> 2009;360:994)</span></p>
<p class="bl"><span class="sbl">•</span> Toxic adenoma or toxic multinodular goiter: RAI or surgery (methimazole preRx for surgery, in selected patients before RAI)</p>
<p class="h2a">Subclinical hyperthyroidism <span class="s">(<i class="calibre3">NEJM</i> 2018;378:2411)</span></p>
<p class="bl"><span class="sbl">•</span> Mild ↓ TSH and <b class="calibre4">normal free T</b><sub class="calibre8"><b class="calibre4">4</b></sub> with only subtle or no sx</p>
<p class="bl"><span class="sbl">•</span> ~15% → overt hyperthyroidism in 2 y; ↑ risk of AF, CHD, fracture <span class="s1r">(<i class="calibre3">JAMA</i> 2015;313:2055)</span></p>
<p class="bl"><span class="sbl">•</span> Rx controversial: consider if TSH &lt;0.1 mU/L and ↑ risk for CV disease or osteopenic</p>
<p class="h2a"><b class="calibre4">Thyroid storm</b> <span class="s">(extremely rare in hyperthyroidism; <i class="calibre3">JCEM</i> 2015;2:451)</span></p>
<p class="bl"><span class="sbl">•</span> Presentation: delirium, fever, tachycardia, systolic HTN w/ wide pulse pressure and ↓ MAP, GI symptoms; 20–30% mortality</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: no universally accepted criteria. Biochemical hyperthyroidism + severe sx, consider additional dx that may explain/contribute to sx.</p>
<p class="bl"><span class="sbl">•</span> Treatment: β-blocker, PTU or methimazole, iopanoic acid or iodide (for Wolff-Chaikoff effect) &gt;1 h after PTU, ± steroids (↓ T<sub class="calibre8">4</sub> → T<sub class="calibre8">3</sub>)</p>
<p class="h"><a id="page_7-6" class="calibre7"></a>N<small class="calibre30">ONTHYROIDAL</small> I<small class="calibre30">LLNESS</small> (S<small class="calibre30">ICK</small> E<small class="calibre30">UTHYROID</small> S<small class="calibre30">YNDROME</small>)<br class="calibre67"/><span class="s1">(<i class="calibre22">J Endocrinol</i> 2010;205:1)</span></p>
<p class="bl"><span class="sbl">•</span> TFT abnormalities in Pts w/ severe nonthyroidal illness (∴ in acute illness, ✔ TFTs only if ↑ concern for thyroid disease); <i class="calibre3">may</i> have acquired transient central hypothyroidism</p>
<p class="bl"><span class="sbl">•</span> If thyroid dysfxn suspected in critically ill Pt, TSH alone not reliable; must measure total T<sub class="calibre8">4</sub>, free T<sub class="calibre8">4</sub>, &amp; T<sub class="calibre8">3</sub></p>
<p class="bl"><span class="sbl">•</span> Mild illness: ↓ T<sub class="calibre8">4</sub> → T<sub class="calibre8">3</sub> conversion, ↑ rT<sub class="calibre8">3</sub> → ↓ T<sub class="calibre8">3</sub>; in severe illness: ↓ TBG &amp; albumin, ↑↑ rT<sub class="calibre8">3</sub> → ↓↓ T<sub class="calibre8">3</sub>, ↑ degradation of T<sub class="calibre8">4</sub>, central ↓ TSH → ↓↓ <b class="calibre4">T<sub class="calibre8">3</sub></b>, ↓↓ <b class="calibre4">T<sub class="calibre8">4</sub></b>, ↓ <b class="calibre4">free T<sub class="calibre8">4</sub></b>, ↓ <b class="calibre4">TSH</b></p>
<p class="bl"><span class="sbl">•</span> Recovery phase: ↑ TSH followed by recovery of T<sub class="calibre8">4</sub> and then T<sub class="calibre8">3</sub></p>
<p class="bl"><span class="sbl">•</span> Replacement thyroxine <i class="calibre3">not</i> helpful or recommended for critically ill Pts w/ ↓ T<sub class="calibre8">3</sub> and T<sub class="calibre8">4</sub> unless other s/s of hypothyroidism</p>
<p class="h">A<small class="calibre30">MIODARONE</small> <small class="calibre30">AND</small> T<small class="calibre30">HYROID</small> D<small class="calibre30">ISEASE</small></p>
<p class="h2a">Overview <span class="s">(<i class="calibre3">JCEM</i> 2010;95:2529)</span></p>
<p class="bl"><span class="sbl">•</span> 6 mg iodine per 200-mg tablet; risk of thyroid dysfunction lower with lower doses</p>
<p class="bl"><span class="sbl">•</span> ✔ TSH prior to therapy, at 4-mo intervals on amio, and for 1 y after if amio d/c’d</p>
<p class="h2a">Hypothyroidism (occurs in ~10%; more common in iodine-replete areas)</p>
<p class="bl"><span class="sbl">•</span> Pathophysiology</p>
<p class="bl2">(1) Wolff-Chaikoff effect: iodine load ↓ I<sup class="calibre15">–</sup> uptake, organification and release of T<sub class="calibre8">4</sub> &amp; T<sub class="calibre8">3</sub></p>
<p class="bl2">(2) inhibits T<sub class="calibre8">4</sub> → T<sub class="calibre8">3</sub> conversion</p>
<p class="bl2">(3) ? direct/immune-mediated thyroid destruction</p>
<p class="bl"><span class="sbl">•</span> Normal individuals: ↓ T<sub class="calibre8">4</sub>; then escape Wolff-Chaikoff effect and have ↑ T<sub class="calibre8">4</sub>, ↓ T<sub class="calibre8">3</sub>, ↑ TSH; then TSH normalizes (after 1–3 mo)</p>
<p class="bl"><span class="sbl">•</span> Susceptible individuals (eg, subclinical Hashimoto’s, ∴ ✔ anti-TPO) do <i class="calibre3">not</i> escape effects</p>
<p class="bl"><span class="sbl">•</span> Treatment: thyroxine to normalize TSH; may need larger than usual dose</p>
<p class="h2a">Hyperthyroidism <span class="s">(3% of Pts on amio; ~</span>1<span class="s">0–20% of Pts</span> <i class="calibre3">in iodine-deficient areas</i><span class="s">)</span></p>
<p class="bl"><span class="sbl">•</span> Type 1 = underlying multinodular goiter or autonomous thyroid tissue</p>
<p class="bl1">Jod-Basedow effect: iodine load → ↑ <b class="calibre4">synthesis</b> of T<sub class="calibre8">4</sub> and T<sub class="calibre8">3</sub> in autonomous tissue</p>
<p class="bl"><span class="sbl">•</span> Type 2 = destructive thyroiditis</p>
<p class="bl1">↑ <b class="calibre4">release</b> of preformed T<sub class="calibre8">4</sub> &amp; T<sub class="calibre8">3</sub> → hyperthyroidism → hypothyroidism → recovery</p>
<p class="bl"><span class="sbl">•</span> Doppler U/S: type 1 w/ ↑ thyroid blood flow; type 2 w/ ↓ flow</p>
<p class="bl"><span class="sbl">•</span> Treatment: not absolutely necessary to d/c amio b/c amio ↓ T<sub class="calibre8">4</sub> → T<sub class="calibre8">3</sub> conversion methimazole for type 1; steroids (eg, 40 mg prednisone qd) for type 2 often difficult to distinguish, so Rx for both typically initiated <span class="s1r">(<i class="calibre3">JCEM</i> 2001;86:3)</span> consider thyroidectomy in severely ill patient</p>
<p class="h">T<small class="calibre30">HYROID</small> C<small class="calibre30">ANCER</small> <span class="s1">(<i class="calibre22">NEJM</i> 2015;373:2347; <i class="calibre22">Thyroid</i> 2016;26:1)</span></p>
<p class="h2a">Thyroid nodules <span class="s">(<i class="calibre3">JAMA</i> 2018;319:914)</span></p>
<p class="bl"><span class="sbl">•</span> Prevalence 5–10% (50–60% if screen with U/S), ♀ &gt; ♂, ~7–15% malignant</p>
<p class="bl"><span class="sbl">•</span> Screening U/S recommended if FHx of MEN2 or medullary thyroid cancer, personal h/o neck XRT, palpable nodules or multinodular goiter</p>
<p class="bl"><span class="sbl">•</span> Features a/w ↑ risk of malig: age &lt;20 or &gt;70 y, ♂, h/o neck XRT, hard &amp; immobile mass, cervical LAN, dysphonia</p>
<p class="bl"><span class="sbl">•</span> U/S features a/w benign dx: cystic nodules, “spongiform” sonographic pattern</p>
<p class="bl"><span class="sbl">•</span> Worrisome findings: hypoechoic, solid, irregular borders, microCa<sup class="calibre15">2</sup><sup class="calibre15">+</sup>, height&gt;width, &gt;20 mm</p>
<p class="bl"><span class="sbl">•</span> Indications for FNA: &gt;10-mm nodule w/ suspicious features</p>
<p class="h2a"><b class="calibre4">Papillary thyroid cancer</b></p>
<p class="bl"><span class="sbl">•</span> Most common form (85% of differentiated thyroid cancers); peak incidence 30 to 50 y</p>
<p class="bl"><span class="sbl">•</span> Risk factors: childhood radiation exposure, FHx in 1° relative, familial syndrome</p>
<p class="bl"><span class="sbl">•</span> Low-risk, mort. 1–2% at 20 y; mets to neck LN common, but prognosis remains good</p>
<p class="bl"><span class="sbl">•</span> Rx is surgery; after surgical resection, RAI if medium or high risk <span class="s1r">(<i class="calibre3">Lancet</i> 2013;381:1046 &amp; 1058)</span></p>
<p class="h2a"><b class="calibre4">Follicular thyroid cancer</b></p>
<p class="bl"><span class="sbl">•</span> Peak incidence 40 to 60 y, ♀:♂ 3:1; RFs: childhood radiation; FHx; familial syndrome</p>
<p class="bl"><span class="sbl">•</span> Mortality 10–20% at 20 y; mets frequently distal due to hematogenous spread</p>
<p class="bl"><span class="sbl">•</span> Hurthle cell carcinoma: pathologic dx; variant a/w poorer prognosis and ↑ recurrence rate</p>
<p class="h2a"><b class="calibre4">Anaplastic thyroid cancer</b> <span class="s">(<i class="calibre3">Endo Metab Clin North Am</i> 2008;37:525)</span></p>
<p class="bl"><span class="sbl">•</span> ♀:♂ 1.5–2:1; poorly differentiated, extremely aggressive, mortality 90% at 5 y</p>
<p class="bl"><span class="sbl">•</span> P/w rapidly growing fixed &amp; hard neck mass, regional or distant spread in 90% at dx</p>
<p class="bl"><span class="sbl">•</span> Rx options include surgery, radiation, trach, chemo, investigational clinical trials</p>
<p class="h2a"><b class="calibre4">Medullary thyroid cancer</b></p>
<p class="bl"><span class="sbl">•</span> Neuroendocrine tumor of C cells, peak incidence 40 to 60 y, a/w MEN2A and MEN2B</p>
<p class="bl"><span class="sbl">•</span> Most commonly solitary nodule; calcitonin production and level used to trend dz progression, dx w/ FNA (Se 50–80%); mortality 25–50% at 5 y</p>
<p class="bl"><span class="sbl">•</span> Surgery first-line treatment</p>
<h2 class="ct"><a id="h95" class="calibre7"></a><a id="page_7-7" class="calibre7"></a><a href="part0002.html#rh105" class="calibre7">ADRENAL DISORDERS</a></h2>
<p class="h">C<small class="calibre30">USHING’S</small> S<small class="calibre30">YNDROME</small> (H<small class="calibre30">YPERCORTISOLISM</small>) <span class="s1">(<i class="calibre22">NEJM</i> 2017;376:1451)</span></p>
<p class="cst"><i class="calibre3">Cushing’s syndrome</i> = <i class="calibre3">cortisol excess</i><br class="calibre6"/><i class="calibre3">Cushing’s disease</i> = <i class="calibre3">Cushing’s syndrome 2° to pituitary ACTH hypersecretion</i></p>
<p class="h2a">Etiologies of hypercortisolism</p>
<p class="bl"><span class="sbl">•</span> Most commonly iatrogenic caused by exogenous glucocorticoids (though underreported)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cushing’s disease</b> (60–70%): ACTH-secreting pituitary adenoma (usually microadenoma) or hyperplasia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Adrenal tumor</b> (15–25%): adenoma or (rarely) carcinoma</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ectopic ACTH</b> (5–10%): SCLC, carcinoid, islet cell tumors, medullary thyroid cancer, pheo</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Lancet</i> 2006;367:13)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Nonspecific:</i> glucose intolerance or DM, HTN, obesity, oligo- or amenorrhea, osteoporosis</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">More specific:</i> central obesity w/ extremity wasting, dorsocervical fat pads, spont. bruising</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Most specific:</i> proximal myopathy, rounded facies, facial plethora, wide purple striae</p>
<p class="bl"><span class="sbl">•</span> Other: depression, insomnia, psychosis, impaired cognition, hypokalemia, acne, hirsutism, hyperpigmentation (if ↑ ACTH), fungal skin infxns, nephrolithiasis, polyuria</p>
<p class="h2a"><b class="calibre4">Diagnosis</b></p>
<p class="bl"><span class="sbl">•</span> Typically performed in <i class="calibre3">outPt</i> setting</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Very difficult as inPt b/c hypercortisolism from acute illness and hosp.</i></p>
<p class="capf"><b class="calibre4">Figure 7-3</b> Approach to suspected Cushing’s syndrome <span class="tfont1">(<i class="calibre3">JCEM</i> 2008;93:1526)</span></p>
<p class="center"><img src="../images/00113.jpeg" alt="" class="calibre2"/></p>
<p class="fnh1">CRH, corticotropin-releasing hormone; DST, dexamethasone suppression test; UFC, urinary free cortisol</p>
<p class="fnh1">Overnight 1 mg DST = give 1 mg at 11 p.m.; ✔ 8 a.m. serum cortisol (suppression if &lt;1.8 μg/dL); &lt;5% false ⊕ (primarily used to evaluate subclinical Cushing’s in adrenal “incidentalomas”)</p>
<p class="fnh1">11 p.m. salivary cortisol = abnl if level ↑; 24-h UFC = abnl if level ↑, &gt; 4× ULN virtually diagnostic</p>
<p class="fnh1">48-h LD DST + CRH = 0.5 mg q6h × 2 d, then IV CRH 2 h later; ✔ serum cortisol 15 min later (⊕ = &gt;1.4 μg/dL)</p>
<p class="fnh1">48-h LD DST = 0.5 mg q6h × 2 d; ✔ 24-h UFC at base. &amp; during last 24 h of dex (suppress if &lt;10% of base)</p>
<p class="fnh1">48-h HD DST = 2 mg q6h × 2 d; ✔ 24-h UFC as per LD DST</p>
<p class="fnh1">O/N HD DST = 8 mg at 11 p.m.; ✔ 9 a.m. serum cortisol (suppression if &lt;32% of baseline)</p>
<p class="fnh1">CRH test = 1 μg/kg IV; ✔ cortisol and ACTH (⊕ stim if &gt; 35% ↑ in ACTH or &gt;20% ↑ in cortisol above baseline)</p>
<p class="fnh">BIPSS, bilat. Inferior petrosal sinus vein sampling; ✔ petrosal:pewwripheral ACTH ratio (⊕ = 2 basal, &gt;3 after CRH)</p>
<p class="h2a">Treatment of Cushing’s syndrome <span class="s">(<i class="calibre3">JCEM</i> 2015;100:2807)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Surgical:</b> resection of pituitary adenoma, adrenal tumor or ectopic ACTH-secreting tumor, or bilat surgical adrenalectomy if unable to control source of ACTH</p>
<p class="bl"><a id="page_7-8" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Medical:</b> cabergoline, pasireotide, mitotane, ketoconazole, or metyrapone to ↓ cortisol, and/or mifepristone to block cortisol action at glucocorticoid receptor; frequently used as bridge to surgery or when surgery contraindicated</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Radiation:</b> can do pituitary XRT, but not effective immediately (takes 6 mo to 2 y)</p>
<p class="bl"><span class="sbl">•</span> Glucocorticoid replacement therapy × 6–36 mo after TSS (lifelong glucocorticoid + mineralocorticoid replacement if medical or surgical adrenalectomy)</p>
<p class="h">H<small class="calibre30">YPERALDOSTERONISM</small></p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Primary</b> (adrenal disorders, renin-independent increase in aldosterone; <i class="calibre3">JCEM</i> 2015;100:1) adrenal hyperplasia (60–70%), adenoma (<b class="calibre4">Conn’s syndrome</b>, 30–40%), carcinoma glucocorticoid-remediable aldosteronism (GRA; ACTH-dep. rearranged promoter)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Secondary</b> (extra-adrenal disorders, ↑ aldosterone is renin-dependent)</p>
<p class="bl1">Primary reninism: renin-secreting tumor (rare)</p>
<p class="bl1">Secondary reninism: renovascular disease: RAS, malignant hypertension; edematous states w/ ↓ effective arterial volume: CHF, cirrhosis, nephrotic syndrome;</p>
<p class="bl2">hypovolemia, diuretics, T2D, Bartter’s (defective Na/K/2Cl transporter ≈ receiving loop diuretic), Gitelman’s (defective renal Na/Cl transporter ≈ receiving thiazide diuretic)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonaldosterone mineralocorticoid excess</b> mimics hyperaldosteronism</p>
<p class="bl1">11β-HSD defic. (→ lack of inactivation of cortisol, which binds to mineralocorticoid recept.)</p>
<p class="bl1">Black licorice (glycyrrhizic acid inhibits 11β-HSD), extreme hypercortisolism (overwhelming 11β-HSD), exogenous mineralocorticoids</p>
<p class="bl1">Liddle’s syndrome (constitutively activated/overexpressed distal tubular renal Na channel)</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mild-to-moderate HTN</b> (11% of Pts w/ HTN refractory to 3 drugs; <i class="calibre3">Lancet</i> 2008;371:1921) headache, muscle weakness, polyuria, polydipsia; no peripheral edema because of “escape” from Na retention; malignant HTN is rare</p>
<p class="bl"><span class="sbl">•</span> Classically <b class="calibre4">hypokalemia</b> (but often normal), metabolic alkalosis, mild hypernatremia</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">JCEM</i> 2008;93:3266; <i class="calibre3">SCNA</i> 2014;94:643)</span></p>
<p class="bl"><span class="sbl">•</span> 5–10% of Pts w/ HTN; ∴ screen if HTN + hypoK, adrenal mass, refractory/early onset HTN</p>
<p class="bl"><span class="sbl">•</span> Screening: <b class="calibre4">aldo</b> (&gt;15–20 ng/dL) <i class="calibre3">and</i> <b class="calibre4">plasma aldo:renin ratio</b> (&gt;20 if 1°) obtain 8 a.m. paired values <span class="s1r">(<i class="calibre3">off</i> spironolactone &amp; eplerenone for 6 wk)</span>; Se &amp; Sp &gt;85%</p>
<p class="bl"><span class="sbl">•</span> ACEI/ARB, diuretics, CCB can ↑ renin activity → ↓ PAC/PRA ratio and βBs may ↑ PAC/PRA ratio;∴ avoid. α-blockers generally best to control HTN during dx testing.</p>
<p class="bl"><span class="sbl">•</span> Confirm with <b class="calibre4">sodium suppression test</b> (fail to suppress aldo after sodium load) oral salt load (+ KCl) × 3 d, ✔ 24-h urine (⊕ if urinary aldo &gt;12 µg/d while urinary Na &gt;200 mEq/d) <i class="calibre3">or</i> 2L NS over 4 h, measure plasma aldo at end of infusion (⊕ if aldo &gt;5 ng/dL)</p>
<p class="capf"><b class="calibre4">Figure 7-4</b> Approach to suspected hyperaldosteronism</p>
<p class="image"><img src="../images/00114.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Surg Clin N Am</i> 2014;94:643)</span></p>
<p class="bl"><span class="sbl">•</span> Adenoma → adrenalectomy vs. medical Rx w/ spironolactone or eplerenone</p>
<p class="bl"><span class="sbl">•</span> Hyperplasia → spironolactone or eplerenone; GRA → glucocorticoids ± spironolactone</p>
<p class="bl"><span class="sbl">•</span> Carcinoma → adrenalectomy</p>
<p class="h"><a id="page_7-9" class="calibre7"></a>A<small class="calibre30">DRENAL</small> I<small class="calibre30">NSUFFICIENCY</small></p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Primary</b> = adrenocortical disease = <b class="calibre4"><i class="calibre3">Addison’s disease</i></b></p>
<p class="bl1"><b class="calibre4">autoimmune:</b> isolated or in assoc w/ APS (see table on <a href="part0012.html#page_7-2" class="calibre1">page 7-2</a>)</p>
<p class="bl1"><b class="calibre4">infection:</b> TB, CMV, histoplasmosis, paracoccidioidomycosis</p>
<p class="bl1"><b class="calibre4">vascular:</b> hemorrhage (usually in setting of sepsis), adrenal vein thrombosis, HIT, trauma</p>
<p class="bl1"><b class="calibre4">metastatic disease:</b> (90% of adrenals must be destroyed to cause insufficiency)</p>
<p class="bl1"><b class="calibre4">deposition diseases:</b> hemochromatosis, amyloidosis, sarcoidosis</p>
<p class="bl1"><b class="calibre4">drugs:</b> azole antifungals, etomidate (even after single dose), rifampin, anticonvulsants</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Secondary</b> = pituitary failure of ACTH secretion (but aldosterone <b class="calibre4">intact</b> b/c RAA axis) any cause of primary or secondary hypopituitarism (see “Pituitary Disorders”)</p>
<p class="bl1">glucocorticoid therapy (can occur after ≤2 wk of “suppressive doses”; dose effect variable; even &lt;10 mg of prednisone daily chronically can be suppressive)</p>
<p class="bl1">megestrol (a progestin with some glucocorticoid activity)</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Lancet</i> 2014;383:2152)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Primary</b> or <b class="calibre4">secondary: weakness and fatigability</b> (99%), <b class="calibre4">anorexia</b> (99%), <b class="calibre4">orthostatic hypotension</b> (90%), nausea (86%), vomiting (75%), hyponatremia (88%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Primary only</b> (extra s/s due to lack of aldosterone and ↑ ACTH): marked <b class="calibre4">orthostatic hypotension</b> (because volume depleted), salt craving, <b class="calibre4">hyperpigmentation</b> (seen in creases, mucous membranes, pressure areas, nipples), <b class="calibre4">hyperkalemia</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Secondary only:</b> ± other manifestations of hypopituitarism (see “Pituitary Disorders”)</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">JCEM</i> 2016;101:364)</span></p>
<p class="bl"><span class="sbl">•</span> Early a.m. serum cortisol: &lt;3 µg/dL virtually diagnostic; ≥18 µg/dL generally consistent with intact adrenal function (see Appendix for examples of test results)</p>
<p class="bl"><span class="sbl">•</span> Standard (250 µg) <b class="calibre4">cosyntropin stimulation test</b> (testing ability of ACTH → ↑ cortisol)</p>
<p class="bl1">normal = 60-min (or 30-min) post-ACTH cortisol ≥18 µg/dL</p>
<p class="bl1">abnormal in <i class="calibre3">primary</i> b/c adrenal gland diseased and unable to give adequate output</p>
<p class="bl1">abnormal in <i class="calibre3">chronic</i> secondary b/c adrenals atrophied and unable to respond</p>
<p class="bl1">(very rarely, may be <i class="calibre3">normal</i> in <i class="calibre3">acute pituitary injury</i> b/c adrenals still able to respond → use early a.m. cortisol instead)</p>
<p class="bl1">All glucocorticoids (incl creams, inh. &amp; drops) affect test. Must know exposure to interpret.</p>
<p class="bl"><span class="sbl">•</span> Other tests (w/ guidance by endocrinologist): renin, aldosterone, insulin-induced hypoglycemia (measure serum cortisol response); metyrapone (blocks cortisol synthesis and therefore stimulates ACTH, measure plasma 11-deoxycortisol and urinary 17-hydroxycorticosteroid levels)</p>
<p class="bl"><span class="sbl">•</span> Other lab abnormalities: hypoglycemia, eosinophilia, lymphocytosis, ± neutropenia</p>
<p class="bl"><span class="sbl">•</span> ACTH: ↑ in 1°, ↓ or low-normal in 2°</p>
<p class="bl"><span class="sbl">•</span> Imaging studies to consider</p>
<p class="bl1">pituitary MRI to detect anatomical abnormalities</p>
<p class="bl1">adrenal CT: small, noncalcified adrenals in autoimmune, enlarged in metastatic disease, hemorrhage, infection or deposition (although they may be normal-appearing)</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Acute</i> insufficiency: volume resusc. w/ normal saline + <b class="calibre4">hydrocortisone IV</b> (see below)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Chronic</i> insufficiency: (1) prednisone ~4–5 mg PO qam or hydrocortisone 15–25 mg PO qd (⅔ a.m., ⅓ early p.m.); (2) fludrocortisone <span class="s1r">(<i class="calibre3">not</i> needed in 2° adrenal insufficiency)</span> 0.05–0.2 mg PO qam <span class="s1r">(<i class="calibre3">JCEM</i> 2018;103:376)</span>; (3) backup dexamethasone 4-mg IM prefilled syringe given to Pt for emergency situations</p>
<p class="h2a">Adrenal insufficiency &amp; critical illness <span class="s">(</span><i class="calibre3">NEJM</i> <span class="s">2003;348:727;</span> <i class="calibre3">JAMA</i> <span class="s">2009;301:2362)</span></p>
<p class="bl"><span class="sbl">•</span> Low cortisol binding proteins; ∴ dx of adrenal insufficiency problematic <span class="s1r">(<i class="calibre3">NEJM</i> 2013;368:1477)</span></p>
<p class="bl"><span class="sbl">•</span> Adrenal insufficiency rare in most cases of shock unless adrenal infarction or bleed, Waterhouse-Friderichson, CNS or pituitary bleed</p>
<p class="bl"><span class="sbl">•</span> Reasonable to perform ACTH stim ASAP in HoTN Pt w/ suspicion for adrenal insufficiency</p>
<p class="bl"><span class="sbl">•</span> Can consider above dx criteria, but decision for Rx should also be based on clinical assessment due to risk of false ⊖ and ⊕ results in context of altered physiology</p>
<p class="bl"><span class="sbl">•</span> If concerned, initiate corticosteroids early: use hydrocortisone 50–100 mg IV q8h; prior to ACTH stim test, use dexamethasone 2–4 mg IV q6h + fludrocortisone 50 µg daily</p>
<p class="bl"><span class="sbl">•</span> Controversial data for empiric steroids in all critically ill Pts (see “Sepsis”)</p>
<p class="h2a"><b class="calibre4">Adrenal crisis in adrenal insufficiency</b> <span class="s">(<i class="calibre3">Lancet Diabetes &amp; Endo</i> 2015;3:216)</span></p>
<p class="bl"><span class="sbl">•</span> Precipitants: bilateral adrenal hemorrhage or infarction, pituitary infarction, pre-existing adrenal insufficiency + serious infection or GI illness</p>
<p class="bl"><span class="sbl">•</span> Presentation: shock + anorexia, N/V, abd pain, weakness, fatigue, confusion, coma, fever</p>
<p class="bl"><span class="sbl">•</span> Lab findings: hyponatremia, hyperkalemia (1°)</p>
<p class="bl"><span class="sbl">•</span> Rx: hydrocortisone 50–100 mg IV q8 + IVF; do not delay for dx tests</p>
<p class="h"><a id="page_7-10" class="calibre7"></a>P<small class="calibre30">HEOCHROMOCYTOMA</small> &amp; P<small class="calibre30">ARAGANGLIOMA</small></p>
<p class="h2a">Clinical manifestations (five Ps) <span class="s">(<i class="calibre3">Lancet</i> 2005;366:665)</span></p>
<p class="bl"><span class="sbl">•</span> Neuroendocrine neoplasm leads to inappropriate and paroxysmal release of adrenergic agents including epinephrine, norephinephrine, and rarely dopamine</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pressure</b> (hypertension, paroxysmal in 50%, severe &amp; resistant to Rx, occ orthostatic)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pain</b> (headache, chest pain)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Palpitations</b> (tachycardia, tremor, wt loss, fever)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Perspiration</b> (profuse)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pallor</b> (vasoconstrictive spell)</p>
<p class="bl"><span class="sbl">•</span> Paroxysms can be triggered by meds (eg, β-blockers) abdominal manipulation</p>
<p class="bl"><span class="sbl">•</span> Associated with MEN2A/2B, von Hippel Lindau, NF1, familial paraganglioma (mutations in succinate dehydrogenase gene B, C and D) or <i class="calibre3">TMEM127</i> mutations</p>
<p class="bl"><span class="sbl">•</span> Up to 40% of pheos/paragangliomas thought to have underlying genetic etiology; genetic testing frequently recommended</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">JCEM</i> 2014;99:1915)</span></p>
<p class="bl"><span class="sbl">•</span> 24° urinary fractionated metanephrines: 85–97% Se, 69–95% Sp. Screening test of choice if low-risk (b/c false ⊕ with severe illness, renal failure, OSA, labetalol due to assay interference, acetaminophen, TCAs, medications containing sympathomimetics).</p>
<p class="bl"><span class="sbl">•</span> Plasma-free metanephrines: 89–100% Se, 79–97% Sp <span class="s1r">(<i class="calibre3">JAMA</i> 2002;287:1427)</span>. Screening test of choice if high risk, but ↑ rate of false ⊕ in low-prevalence population. False ⊕ rate lower if patient supine for 30 min (estimated 2.8× ↑ false ⊕ if seated).</p>
<p class="bl"><span class="sbl">•</span> Adrenal CT generally better than MRI; PET for known metastatic disease or to localize nonadrenal mass but usually easy to find; consider MIBG scintigraphy if CT/MRI ⊖</p>
<p class="bl"><span class="sbl">•</span> Consider genetic testing if bilateral disease, young Pt, ⊕ FHx, extra-adrenal</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> α-blockade first (usually phenoxybenzamine) ± β-blockade (often propranolol) → surgery</p>
<p class="bl"><span class="sbl">•</span> Preoperative volume expansion is critical due to possible hypotension after tumor excision</p>
<p class="h">A<small class="calibre30">DRENAL</small> I<small class="calibre30">NCIDENTALOMAS</small></p>
<p class="h2a">Epidemiology</p>
<p class="bl"><span class="sbl">•</span> 4% of Pts undergoing abdominal CT scan have incidentally discovered adrenal mass; prevalence ↑ with age</p>
<p class="h2a">Differential diagnosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonfunctioning mass:</b> adenoma, cysts, abscesses, granuloma, hemorrhage, lipoma,</p>
<p class="bl1">myelolipoma, primary or metastatic malignancy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Functioning mass:</b> pheochromocytoma, adenoma (cortisol, aldosterone, sex hormones), nonclassical CAH, other endocrine tumor, carcinoma</p>
<p class="h2a">Hormonal workup <span class="s">(<i class="calibre3">NEJM</i> 2007;356:601; <i class="calibre3">EJE</i> 2016;175:G1)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rule out subclinical Cushing’s syndrome</b> <i class="calibre3">in all Pts</i> using 1 mg overnight DST (Sp 91%). Abnormal results require confirmatory testing.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rule out hyperaldosteronism</b> <i class="calibre3">if hypertensive</i> w/ plasma aldo &amp; renin (see above)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rule out pheochromocytoma</b> <i class="calibre3">in ALL Pts</i> (b/c of morbidity unRx’d pheo) using 24-h urine fractionated metanephrines or plasma-free metanephrines</p>
<p class="h2a">Malignancy workup</p>
<p class="bl"><span class="sbl">•</span> CT and MRI characteristics may suggest adenoma vs. carcinoma</p>
<p class="bl1"><i class="calibre3">Benign features:</i> unenhanced CT &lt;10 Hounsfield units or CT contrast-medium washout &gt;50% at 10 min; size &lt;4 cm; smooth margins, homogenous and hypodense appearance; can follow such incidentalomas w/ periodic scans</p>
<p class="bl1"><i class="calibre3">Suspicious features:</i> size &gt;6 cm or ↑ size on repeat scan; irregular margins, heterogeneous, dense or vascular appearance; h/o malignancy or young age. Such incidentalomas warrant resection or repeat scan at short interval.</p>
<p class="bl"><span class="sbl">•</span> Rule out metastatic cancer (and infection) in Pts w/ h/o cancer; ~50% of adrenal incidentalomas are malignant</p>
<p class="h2a">Follow-up</p>
<p class="bl"><span class="sbl">•</span> If hormonal workup ⊖ and appearance benign, yearly fxnal testing for 4 y w/ follow-up imaging at 6, 12, &amp; 24 mo reasonable approach, but controversial</p>
<h2 class="ct"><a id="h96" class="calibre7"></a><a id="page_7-11" class="calibre7"></a><a href="part0002.html#rh106" class="calibre7">CALCIUM DISORDERS</a></h2>
<p class="image1"><img src="../images/00115.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Pitfalls in measuring calcium</p>
<p class="bl"><span class="sbl">•</span> Physiologically active Ca is free or ionized (ICa). Serum Ca reflects total calcium (bound + unbound) and ∴ influenced by albumin (main Ca-binding protein).</p>
<p class="bl"><span class="sbl">•</span> Corrected Ca (mg/dL) = measured Ca (mg/dL) + {0.8 × [4 – albumin (g/dL)]}</p>
<p class="bl"><span class="sbl">•</span> Alkalosis will cause more Ca to be bound to albumin (∴ total Ca may be normal but ↓ ICa)</p>
<p class="bl"><span class="sbl">•</span> Best to measure <b class="calibre4">ionized Ca directly</b> <i class="calibre3">(but accuracy is lab dependent)</i></p>
<p class="h">H<small class="calibre30">YPERCALCEMIA</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre68"/>
<col class="calibre69"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Etiologies of Hypercalcemia</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Category</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Hyperparathyroidism</b> (<b class="calibre4">HPT</b>)</p>
<p class="tab"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">8;379:</span><span class="tfont1">1</span><span class="tfont1">05;</span> <span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">8;39</span><span class="tfont1">1</span><span class="tfont1">:</span><span class="tfont1">1</span><span class="tfont1">68)</span></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">1</b>°: <b class="calibre4">adenoma</b> (85%), hyperplasia (15–20%; spont. vs. MEN1/2A), carcinoma (&lt;1%), meds (Lithium → ↑ PTH)</p>
<p class="tabh"><b class="calibre4">3</b>°: after long-standing 2° hyperparathyroidism (as in renal failure) → autonomous nodule develops, requires surgery</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Familial hypocalciuric hypercalcemia</b> (<b class="calibre4">FHH</b>)</p></td>
<td class="bg0-b"><p class="tabh">Inact. mut. in Ca-sensing receptor (FHH1), Gα11 (FHH2), AP2S1 (FHH3) → ↑ Ca set point; ± mild ↑ PTH</p>
<p class="tab">Acquired form due to autoAb vs. Ca-sensing receptor (rare)</p>
<p class="tab">FE<sub class="calibre13">Ca</sub> [(24-h U<sub class="calibre13">Ca</sub>/serum Ca) / (24-h U<sub class="calibre13">Cr</sub>/serum Cr)] &lt;0.01</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Malignancy</b></p>
<p class="tab"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">JCEM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">5;</span><span class="tfont1">1</span><span class="tfont1">00:2024)</span></p></td>
<td class="bg0-b"><p class="tabh">PTH-related peptide (PTHrP) → humoral ↑ Ca of malignancy (eg, squamous cell cancers, renal, breast, bladder)</p>
<p class="tab">Cytokines → ↑ osteoclast activity (eg, hematologic malig)</p>
<p class="tab">↑ 1,25-(OH)<sub class="calibre13">2</sub>D (eg, rare lymphomas)</p>
<p class="tab">Local osteolysis (eg, breast cancer, myeloma)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Vitamin D excess</b></p></td>
<td class="bg0-b"><p class="tab">Granulomas (sarcoid, TB, histo, GPA) → ↑ 1-OHase → ↑ 1,25-(OH)<sub class="calibre13">2</sub>D. Vitamin D intoxication.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">↑ <b class="calibre4">Bone turnover</b></p></td>
<td class="bg0-b"><p class="tab">Hyperthyroidism, immobilization + Paget’s disease, vitamin A</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Miscellaneous</b></p></td>
<td class="bg0-b"><p class="tab">Thiazides; Ca-based antacids or massive dairy consumption (milk-alkali syndrome); adrenal insufficiency</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2"><p class="tab"><i class="calibre3">Among inPts w/ hypercalcemia: 45% have cancer, 25% 1° HPT, 10% CKD</i> → <i class="calibre3">3</i>° <i class="calibre3">HPT</i></p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">JCEM</i> 2005;90:6316; <i class="calibre3">NEJM</i> 2013;368:644)</p>
<p class="h2a">Clinical manifestations <span class="s">(“bones, stones, abdominal groans, and psychic moans”)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypercalcemic crisis</b> (usually when Ca &gt;13–15): polyuria, dehydration, ΔMS</p>
<p class="bl1">Ca toxic to renal tubules → blocks ADH activity, causes vasoconstriction and ↓ GFR → polyuria but Ca reabsorption → ↑ serum Ca → ↑ nephrotoxicity and CNS sx</p>
<p class="bl"><span class="sbl">•</span> Osteopenia, fractures, and osteitis fibrosa cystica (latter seen in severe hyperpara. only →</p>
<p class="bl1">↑ osteoclast activity → cysts, fibrous nodules, salt &amp; pepper appearance on X-ray)</p>
<p class="bl"><span class="sbl">•</span> Nephrolithiasis, nephrocalcinosis, nephrogenic DI</p>
<p class="bl"><span class="sbl">•</span> Abdominal pain, anorexia, nausea, vomiting, constipation, pancreatitis, PUD</p>
<p class="bl"><span class="sbl">•</span> Fatigue, weakness, depression, confusion, coma, ↓ DTRs, short QT interval</p>
<p class="bl"><span class="sbl">•</span> 1° HPT: 80% asx, 20% nephrolithiasis, osteoporosis, etc.</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Hyperparathyroidism (HPT) and malignancy account for 90% of cases of ↑ Ca; HPT more likely if asx or chronic; malignancy (usually overt) more likely if acute or sx</p>
<p class="bl"><span class="sbl">•</span> Ca, alb, ICa, PTH (may be inapprop. normal in 1° HPT &amp; FHH; <i class="calibre3">JAMA</i> 2014;312:2680), PO<sub class="calibre8">4</sub>;</p>
<p class="bl1">↑ or high nl PTH: 24-h U<sub class="calibre8">Ca</sub> &gt;200 mg → HPT; 24-h U<sub class="calibre8">Ca</sub> &lt;100 mg &amp; FE<sub class="calibre8">Ca</sub> &lt;0.01 → FHH</p>
<p class="bl1"><a id="page_7-12" class="calibre1"></a>↓ PTH: ✔ PTHrP, Aϕ, &amp; search for malig (eg, CT, mammogram, SPEP/UPEP) and ✔ vit D: ↑ 25-(OH)D → meds; ↑ 1,25-(OH)<sub class="calibre8">2</sub>D → granuloma (✔ CXR, ACE, r/o lymph)</p>
<p class="imagef"><img src="../images/00116.jpeg" alt="" class="calibre2"/></p>
<p class="fn">(<i class="calibre3">BMJ</i> 2015;350:h2723)</p>
<p class="h2a">Treatment of asymptomatic 1° HPT <span class="s">(<i class="calibre3">JCEM</i> 2014;99:3561)</span></p>
<p class="bl"><span class="sbl">•</span> Surgery if: age &lt;50 y; serum Ca &gt;1 mg/dL &gt;ULN; CrCl &lt;60 mL/min, DEXA T score &lt;–2.5</p>
<p class="bl"><span class="sbl">•</span> If surgery declined/deferred, can Rx with cinacalcet (↓ Ca &amp; PTH but may not ↑ BMD)</p>
<p class="bl"><span class="sbl">•</span> If not yet candidate for surgery: ✔ serum Ca &amp; Cr annually and BMD q2y</p>
<p class="h2a">Calciphylaxis <span class="s">(calcific uremic arteriolopathy)</span></p>
<p class="bl"><span class="sbl">•</span> Calcification of media of small- to med-sized blood vessels of dermis &amp; SC fat</p>
<p class="bl"><span class="sbl">•</span> Ischemia &amp; skin necrosis. See “Chronic Kidney Disease” for further details.</p>
<p class="h">H<small class="calibre30">YPOCALCEMIA</small></p>
<table class="t-topbot2">
<colgroup class="calibre9">
<col class="calibre68"/>
<col class="calibre69"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Etiologies of Hypocalcemia</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Category</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Hypoparathyroidism</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">9;380:</span><span class="tfont">1</span><span class="tfont1">738)</span></p></td>
<td class="bg0-b"><p class="tab">Iatrogenic (s/p thyroidectomy, rarely after parathyroidectomy); sporadic; familial (APS1, activating Ca-sensing receptor mutations; see <a href="part0012.html#page_7-2" class="calibre1">page 7-2</a>); Wilson’s, hemochromatosis; hypoMg (↓ secretion and effect); activating Ca-sensing receptor autoAb</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pseudo- hypoparathyroidism</b></p>
<p class="tab"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">JCEM</i></span> <span class="tfont1">20</span><span class="tfont">11</span><span class="tfont1">;96:3020)</span></p></td>
<td class="bg0-b"><p class="tab">Ia and Ib: PTH end-organ resistance (∴ ↑ serum PTH) Ia: + skeletal abnormalities, short stature, &amp; retardation Pseudopseudohypoparathyroidism = Ia syndrome but <i class="calibre3">nl</i> Ca &amp; PTH</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Vit D defic. or resist</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">11</span><span class="tfont1">;364:248;</span> <span class="tfont1"><i class="calibre3">JCEM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">2;97:</span><span class="tfont">11</span><span class="tfont1">53)</span></p></td>
<td class="bg0-b"><p class="tab">Nutritional/sunlight deprivation; GI disease/fat malabs.; drugs (anticonvulsants, rifampin, ketoconazole, 5-FU/leucovorin); genetic (1α-hydroxylase, VDR mutations)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Chronic renal failure</b></p></td>
<td class="bg0-b"><p class="tab">↓ 1,25-(OH)<sub class="calibre13">2</sub>D production, ↑ PO<sub class="calibre13">4</sub> from ↓ clearance</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Accelerated net bone formation</b></p></td>
<td class="bg0-b"><p class="tab">Postparathyroidectomy, Paget’s disease <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">3;368:644)</span>, osteoblastic metastases</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Calcium sequestration</b></p></td>
<td class="bg"><p class="tab">Pancreatitis, citrate excess (after blood transfusions), acute ↑↑ PO<sub class="calibre13">4</sub> (ARF, rhabdomyolysis, tumor lysis), bisphosphonates</p></td>
</tr>
</table>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neuromuscular irritability:</b> perioral paresthesias, cramps, ⊕ <b class="calibre4">Trousseau’s</b> (inflation of BP cuff ≥3 min → carpal spasm), ⊕ <b class="calibre4">Chvostek’s</b> (tapping facial nerve → contraction of facial muscles), laryngospasm; irritability, depression, psychosis, seizures, ↑ QT</p>
<p class="bl"><span class="sbl">•</span> Rickets and/or osteomalacia: chronic ↓ vit D → ↓ Ca, ↓ PO<sub class="calibre8">4</sub> → ↓ bone/cartilage mineralization, growth failure, bone pain, muscle weakness</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Renal osteodystrophy</b> (↓ vit D &amp; ↑ PTH in renal failure): osteomalacia [↓ mineralization of bone due to ↓ Ca and 1,25-(OH)<sub class="calibre8">2</sub>D] &amp; osteitis fibrosa cystica (due to ↑ PTH)</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Ca, alb, ICa, PTH, 25-(OH)D, 1,25-(OH)<sub class="calibre8">2</sub>D (if renal failure or rickets), Cr, Mg, PO<sub class="calibre8">4</sub>, Aϕ, U<sub class="calibre8">Ca</sub></p>
<p class="h2a">Treatment <span class="s2">(also treat concomitant vitamin D deficiency)</span></p>
<p class="bl"><span class="sbl">•</span> Severely symptomatic: Ca gluconate (1–2 g IV over 20 min) + oral Ca + calcitriol (but takes hrs to work) ± Mg (50–100 mEq/d); 10% CaCl<sub class="calibre8">2</sub> in codes or via CVL</p>
<p class="bl"><span class="sbl">•</span> Consider Ca gtt or PO to follow b/c effect of IV bolus typically lasts only a few hours</p>
<p class="bl"><span class="sbl">•</span> Chronic (depends on etiol.): oral Ca (1–3 g/d; citrate better absorbed than carbonate, esp. if achlorhydria or on PPI) and typically calcitriol (0.25–2 mcg/d), and replete vit. D defic. Consider thiazide to ↓ urinary Ca or recombinant PTH 1-84 (if hypopara).</p>
<p class="bl"><span class="sbl">•</span> Chronic renal failure: phosphate binder(s), oral Ca, calcitriol or analogue</p>
<h2 class="ct"><a id="h97" class="calibre7"></a><a id="page_7-13" class="calibre7"></a><a href="part0002.html#rh107" class="calibre7">DIABETES MELLITUS</a></h2>
<p class="h2a">Definition <span class="s">(<i class="calibre3">Diabetes Care</i> 2019;42:S13)</span></p>
<p class="bl"><span class="sbl">•</span> Either Hb<sub class="calibre8">A1c</sub> ≥6.5, fasting glc ≥126 mg/dL, or glc 2 h after OGTT ≥200 mg/dL × 2 (for any test) or single random glc ≥200 mg/dL w/ classic sx of hyperglycemia; all tests equally reasonable (nb, may be ⊕ on one test but not another); OGTT preferred during preg</p>
<p class="bl"><span class="sbl">•</span> Blood glc higher than normal, but not frank DM (“prediabetics,” ~40% U.S. population)</p>
<p class="bl1">Hb<sub class="calibre8">A1c</sub> 5.7–6.4%, impaired fasting glc (IFG) 100–125 mg/dL, or 2 h prandial glc 140–199</p>
<p class="bl1">Preventing progression to DM: diet &amp; exercise (58% ↓), metformin (31% ↓; <i class="calibre3">NEJM</i> 2002;346:393), TZD (60% ↓; <i class="calibre3">Lancet</i> 2006;368:1096)</p>
<p class="h2a">Categories</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Type 1</b> <span class="s1r">(<i class="calibre3">Lancet</i> 2018;391:2449)</span>: islet cell destruction; absolute insulin deficiency; ketosis in absence of insulin; prevalence 0.4%; usual onset in childhood but can occur throughout adulthood; ↑ risk if ⊕ FHx; HLA associations; anti-GAD, anti-islet cell &amp; anti-insulin autoAb</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Type 2</b> <span class="s1r">(<i class="calibre3">Lancet</i> 2017;389:2239)</span>: insulin resistance + relative insulin ↓; prevalence 6%; onset generally later in life; no HLA assoc.; risk factors: age, ⊕ FHx, obesity, sedentary lifestyle</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Type 2 DM p</b>/<b class="calibre4">w DKA</b> (“ketosis-prone type 2 diabetes” or “Flatbush diabetes”): most often seen in nonwhite, ± anti-GAD Ab, eventually may not require insulin <span class="s1r">(<i class="calibre3">Endo Rev</i> 2008;29:292)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">M</b>ature-<b class="calibre4">O</b>nset <b class="calibre4">D</b>iabetes of the <b class="calibre4">Y</b>oung (<b class="calibre4">MODY</b>): autosomal dom. forms of DM due to defects in insulin secretion genes; genetically and clinically heterogeneous <span class="s1r">(<i class="calibre3">NEJM</i> 2001;345:971)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Secondary causes of diabetes:</b> exogenous glucocorticoids, glucagonoma (3 Ds = DM, DVT, diarrhea), pancreatic (pancreatitis, hemochromatosis, CF, resection), endocrinopathies (Cushing’s disease, acromegaly), gestational, drugs (protease inhibitors, atypical antipsychotics)</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Polyuria, polydipsia, polyphagia with unexplained weight loss; can also be asymptomatic</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Diabetes Treatment Options</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Medication</b> (↓ Hb<sub class="calibre13">A</sub><sub class="calibre13">1</sub><sub class="calibre13">C</sub>)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Comments</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Metformin</b> (~1–1.5%)</p></td>
<td class="bg0-b"><p class="tab">↓ hepatic gluconeogenesis. Mild wt ↓. <i class="calibre3">1<sup class="calibre35">st</sup> line for T2D.</i> Rare lactic acidosis. Caution if GFR 30–45; contra. if &lt;30. Poss CV benefit.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">DPP-4 inhibitors</b></p>
<p class="tab">(~0.5–1%)</p></td>
<td class="bg0-b"><p class="tab">Block degrad. GLP-1 &amp; GIP → ↑ insulin.</p>
<p class="tab">↑ risk of HF w/ saxagliptin <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">3;369:</span><span class="tfont">1</span><span class="tfont1">3</span><span class="tfont">1</span><span class="tfont1">7)</span>, not w/ others.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">GLP-1 receptor agonists</b> (~1–1.5%)</p></td>
<td class="bg0-b"><p class="tab">↑ glc-depend insulin secretion. Wt ↓, N/V.</p>
<p class="tab">↓ CVD/MI/stroke, espec. if ASCVD. ↓ prog of albuminuria.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">SGLT-2 inhibitors</b></p>
<p class="tab">(~0.5–1%)</p></td>
<td class="bg0-b"><p class="tab">↑ glucosuria. Wt ↓. Genital infxn. ↓ CVD/HHF. ↓ CVD &amp; MI if ASCVD. ↓ prog. of renal disease.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Sulfonylureas (SU)</b> (~1.5%)</p></td>
<td class="bg0-b"><p class="tab">↑ insulin secretion. Hypoglycemia; wt gain.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Thiazolidinediones (TZD)</b> (~1%)</p></td>
<td class="bg0-b"><p class="tab">↑ insulin sens. in adipose &amp; muscle. Wt ↑, fluid retention &amp; CHF. Hepatox. ↑ MI w/ rosiglitazone? Contraindic. in HF &amp; liver dysfxn.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Glinides</b> (~1%)</p></td>
<td class="bg0-b"><p class="tab">↑ insulin secretion; hypoglycemia; wt gain</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">α<b class="calibre4">-glucosidase inhib.</b> (0.5–1%)</p></td>
<td class="bg0-b"><p class="tab">↓ intestinal CHO absorption. Abd pain, flatulence.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pramlintide</b> (~0.5%)</p></td>
<td class="bg0-b"><p class="tab">Delays gastric emptying &amp; ↓ glucagon. N/V</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Insulin</b></p>
<p class="tab">(variable)</p></td>
<td class="bg0-b"><p class="tab">Hypoglycemia; wt gain. Mandatory in T1D; consider in T2D if oral Rx inadequate.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Gastric bypass</p></td>
<td class="bg"><p class="tab">Wt ↓↓↓; can cause remission DM <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">4;370:2002)</span></p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">Diabetes Care</i> 2019;42:S90; <i class="calibre3">Lancet</i> 2019;393:31; <i class="calibre3">Circ</i> 2019;139:2022; <i class="calibre3">NEJM</i> 2019;380:2295)</p>
<p class="image1"><img src="../images/00117.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Complications <span class="s">(<i class="calibre3">NEJM</i> 2004;350:48; 2016;374:1455; <i class="calibre3">CJASN</i> 2017;12:1366)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Retinopathy</b></p>
<p class="bl1"><i class="calibre3">nonproliferative:</i> “dot &amp; blot” and retinal hemorrhages, cotton-wool/protein exudates</p>
<p class="bl1"><i class="calibre3">proliferative:</i> neovascularization, vitreous hemorrhage, retinal detachment, blindness</p>
<p class="bl1">treatment: photocoagulation, surgery, intravitreal bevacizumab injections</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nephropathy:</b> microalbuminuria → proteinuria ± nephrotic syndrome → renal failure</p>
<p class="bl1">diffuse glomerular basement membrane thickening/nodular pattern (Kimmelstiel-Wilson)</p>
<p class="bl1">usually accompanied by retinopathy; lack of retinopathy suggests another cause</p>
<p class="bl1"><a id="page_7-14" class="calibre1"></a>treatment: strict BP control using ACE inhibitors or ARBs <span class="s1r">(<i class="calibre3">Mayo Clin Proc</i> 2011;86:444)</span>, SGLT-2 inhib <span class="s1r">(<i class="calibre3">NEJM</i> 2016;375:323 &amp; 2019;380:2295)</span>, low-protein diet, dialysis or transplant</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neuropathy:</b> <i class="calibre3">peripheral:</i> symmetric distal sensory loss, paresthesias, ± motor loss</p>
<p class="bl1"><i class="calibre3">autonomic:</i> gastroparesis, constipation, neurogenic bladder, erectile dysfxn, orthostasis</p>
<p class="bl1"><i class="calibre3">mononeuropathy:</i> sudden-onset peripheral or CN deficit (footdrop, CN III &gt; VI &gt; IV)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Accelerated atherosclerosis:</b> coronary, cerebral and peripheral arterial beds</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infections:</b> UTI, osteomyelitis of foot, candidiasis, mucormycosis, necrotizing external otitis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dermatologic:</b> necrobiosis lipoidica diabeticorum, lipodystrophy, acanthosis nigricans</p>
<p class="h2a">Outpatient screening and treatment goals <span class="s">(</span><i class="calibre3">Diabetes Care</i> <span class="s">2019;42:S61, S81, S103)</span></p>
<p class="bl"><span class="sbl">•</span> ✔ Hb<sub class="calibre8">A1C</sub> q3–6mo, goal &lt;7% for most Pts. Goal &lt;6.5% if low-risk hypoglycemia; ≤8% if h/o severe hypoglycemia, elderly or other comorbid. Microvascular &amp; macrovascular complic. ↓ by strict glycemic control in T1D <span class="s1r">(<i class="calibre3">NEJM</i> 2005;353:2643)</span> &amp; T2D <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:2197)</span>.</p>
<p class="bl"><span class="sbl">•</span> Microalbuminuria screening yearly with spot microalbumin/Cr ratio, goal &lt;30 mg/g</p>
<p class="bl"><span class="sbl">•</span> Wt loss (dietary/drugs) can regress or resolve DM <span class="s1r">(<i class="calibre3">Endo Rev</i> 2018;39:79; <i class="calibre3">NEJM</i> 2018;379:1107)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">BP</b> ≤130/80 if high CV risk, ≤140/90 if lower risk; benefit of ACEI/ARB</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lipids:</b> statin initiation in all diabetics age 40–75 if LDL-C &gt;70 (see “Lipids”)</p>
<p class="bl"><span class="sbl">•</span> ASA in 2° prevention; ? role in 1°, balancing ↓ MACE &amp; ↑ bleeding <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:1529)</span></p>
<p class="bl"><span class="sbl">•</span> Dilated retinal exam and comprehensive foot exam yearly</p>
<p class="h2a">Management of hyperglycemia in inPts <span class="s">(for ICU: see “Sepsis”) (<i class="calibre3">ClinTher</i> 2013;35:724)</span></p>
<p class="bl"><span class="sbl">•</span> Identify reversible causes/precipitants (dextrose IVF, glucocorticoids, postop, ↑ carb diet)</p>
<p class="bl"><span class="sbl">•</span> Dx studies: BG fingersticks (fasting, qAC, qHS; or q6h if NPO), Hb<sub class="calibre8">A1C</sub></p>
<p class="bl"><span class="sbl">•</span> Treatment goals: avoid hypoglycemia, extreme hyperglycemia (&gt;180 mg/dL)</p>
<p class="bl"><span class="sbl">•</span> Transition to inPt</p>
<p class="bl1">T1D: do not stop basal insulin (can → DKA)</p>
<p class="bl1">T2D: stopping oral DM meds generally preferred to avoid hypoglycemia or med interaction (except if short stay, excellent outPt cntl, no plan for IV contrast, nl diet). <i class="calibre3">If Pt w/ known insulin needs do not rely on sliding scale alone</i> <span class="s1r">(<i class="calibre3">Diabetes Care</i> 2018;41:S144)</span>.</p>
<p class="bl"><span class="sbl">•</span> Starting new insulin regimen</p>
<p class="bl1">Basal = 0.2–0.4 u/kg/d NPH Q12h or detemir or glargine</p>
<p class="bl1">+ correction insulin for BG &gt;150 mg/dl</p>
<p class="bl1">+ prandial insulin if eating<b class="calibre4">:</b> 0.05–0.1 μ/kg/meal lispro, aspart, or regular</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">When NPO</i></p>
<p class="bl1">T1D: continue basal insulin at current dose or 75% depending on BG control</p>
<p class="bl1">T2D: continue basal insulin at 25–75% depending on BG control and level of insulin resistance. Hold all prandial insulin.</p>
<p class="bl"><span class="sbl">•</span> Discharge regimen: similar to admission regimen unless poor outPt cntl or strong reason for Δ. Arrange early insulin and glucometer teaching, prompt outPt follow-up.</p>
<p class="h">D<small class="calibre30">IABETIC</small> K<small class="calibre30">ETOACIDOSIS</small> (DKA)</p>
<p class="h2a">Precipitants (the I’s)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Insulin defic.</b> (ie, failure to take enough insulin); <b class="calibre4">Iatrogenesis</b> (glucocorticoids; SGLT2 inhibitors—can be w/o marked hyperglycemia; <i class="calibre3">Diabetes Care</i> 2016;39:532)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infection</b> (pneumonia, UTI) or <b class="calibre4">Inflammation</b> (pancreatitis, cholecystitis)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ischemia</b> or <b class="calibre4">Infarction</b> (myocardial, cerebral, gut); <b class="calibre4">Intoxication</b> (alcohol, drugs)</p>
<p class="h2a">Pathophysiology <span class="s">(<i class="calibre3">NEJM</i> 2015;372:546)</span></p>
<p class="bl"><span class="sbl">•</span> Occurs in <b class="calibre4">T1D</b> (and in ketosis-prone T2D); ↑ glucagon and ↓ insulin</p>
<p class="bl"><span class="sbl">•</span> Hyperglycemia due to: ↑ gluconeogenesis, ↑ glycogenolysis, ↓ glucose uptake into cells</p>
<p class="bl"><span class="sbl">•</span> Ketosis due to: insulin deficiency → mobilization and oxidation of fatty acids,</p>
<p class="bl1">↑ substrate for ketogenesis, ↑ ketogenic state of the liver, ↓ ketone clearance</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Diabetes Care</i> 2009;32:1335 &amp; 2016;39:S99)</span></p>
<p class="bl"><span class="sbl">•</span> Polyuria, polydipsia, &amp; dehydration → ↑ HR, HoTN, dry mucous membranes, ↓ skin turgor</p>
<p class="bl"><span class="sbl">•</span> N/V, abdominal pain (either due to intra-abdominal process or DKA), ileus</p>
<p class="bl"><span class="sbl">•</span> Kussmaul’s respirations (deep) to compensate for metabolic acidosis with odor of acetone</p>
<p class="bl"><span class="sbl">•</span> Δ MS → somnolence, stupor, coma; mortality ~1% even at tertiary care centers</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">Anion gap metabolic acidosis:</b> can later develop nonanion gap acidosis due to urinary loss of ketones (HCO<sub class="calibre8">3</sub> equivalents) and fluid resuscitation with chloride</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ketosis:</b> ⊕ <b class="calibre4">urine and serum ketones</b> (predominant ketone is β-OH-butyrate, but acetoacetate measured by assay; urine ketones may be ⊕ in fasting normal Pts)</p>
<p class="bl"><span class="sbl">•</span> ↑ Serum glc; ↑ BUN &amp; Cr (dehydration ± artifact due to ketones interfering w/ some assays)</p>
<p class="bl"><span class="sbl">•</span> Hyponatremia: corrected Na = measured Na + [2.4 × (measured glc – 100)/100]</p>
<p class="bl"><span class="sbl">•</span> ↓ or ↑ K (but even if serum K is elevated, usually <i class="calibre3">total body K depleted</i>); ↓ total body phos</p>
<p class="bl"><span class="sbl">•</span> Leukocytosis, ↑ amylase (even if no pancreatitis)</p>
<p class="image1"><a id="page_7-15" class="calibre1"></a><img src="../images/00118.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre68"/>
<col class="calibre69"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Treatment of DKA</b> <span class="tfont1">(<i class="calibre3">BMJ</i> 2015;28:351)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">R/o possible precipitants</b></p></td>
<td class="bg0-b"><p class="tab">Infection, intra-abdominal process, MI, etc. (see above)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Aggressive hydration</b></p></td>
<td class="bg0-b"><p class="tab">NS 10–14 mL/kg/h, tailor to dehydration &amp; CV status</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Insulin</b></p></td>
<td class="bg0-b"><p class="tab">10 U IV push followed by 0.1 U/kg/h</p>
<p class="tab">Continue insulin drip until AG normal</p>
<p class="tabh">If glc &lt;250 and AG still high → add dextrose to IVF and continue insulin to metabolize ketones</p>
<p class="tab">AG normal → SC insulin (overlap IV &amp; SC 2–3 h)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Electrolyte repletion</b></p></td>
<td class="bg"><p class="tabh">K: add 20–40 mEq/L IVF if serum K &lt;4.5 insulin promotes K entry into cells → ↓ serum K careful K repletion in Pts with renal failure</p>
<p class="tab">HCO<sub class="calibre13">3</sub>: ? replete if pH &lt;7 or if cardiac instability</p>
<p class="tab">PO<sub class="calibre13">4</sub>: replete if &lt;1</p></td>
</tr>
</table>
<p class="h">H<small class="calibre30">YPEROSMOLAR</small> H<small class="calibre30">YPERGLYCEMIC</small> S<small class="calibre30">TATE</small></p>
<p class="h2a">Definition, precipitants, pathophysiology <span class="s">(<i class="calibre3">Med Clin North Am</i> 2017;101:587)</span></p>
<p class="bl"><span class="sbl">•</span> Extreme hyperglycemia (w/o ketoacidosis) + hyperosm. + Δ MS in T2D (typically elderly)</p>
<p class="bl"><span class="sbl">•</span> Precip same as for DKA, but also include dehydration and renal failure</p>
<p class="bl"><span class="sbl">•</span> Hyperglycemia → osmotic diuresis → vol depletion → prerenal azotemia → ↑ glc, etc.</p>
<p class="h2a">Clinical manifestations &amp; dx studies <span class="s">(<i class="calibre3">Diabetes Care</i> 2014;37:3214)</span></p>
<p class="bl"><span class="sbl">•</span> Volume depletion and Δ MS</p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">serum glc</b> (usually &gt;600 mg/dL) and ↑ <b class="calibre4">meas. serum osmolality</b> (&gt;320 mOsm/L) effective Osm = 2 × Na (mEq/L) + glc (mg/dL)/18</p>
<p class="bl"><span class="sbl">•</span> No ketoacidosis; usually ↑ BUN &amp; Cr; [Na] depends on hyperglycemia &amp; dehydration</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Rule-out possible precipitants; ~15% mortality due to precipitating factors</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aggressive hydration:</b> initially NS, then 1/2 NS, average fluid loss up to 8–10 L</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Insulin</b> (eg, 10 U IV followed by 0.05–0.1 U/kg/h)</p>
<p class="h">H<small class="calibre30">YPOGLYCEMIA</small></p>
<p class="h2a">Clinical manifestations (glucose &lt;~55 mg/dL)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CNS:</b> headache, visual Δs, Δ MS, weakness, seizure, LOC (neuroglycopenic sx)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Autonomic:</b> diaphoresis, palpitations, tremor (adrenergic sx)</p>
<p class="h2a">Etiologies in diabetics</p>
<p class="bl"><span class="sbl">•</span> Excess insulin, oral hypoglycemics, missed meals, renal failure (↓ insulin &amp; SU clearance)</p>
<p class="bl"><span class="sbl">•</span> β-blockers can mask adrenergic symptoms of hypoglycemia</p>
<p class="h2a">Etiologies in nondiabetics</p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">insulin:</b> exogenous insulin, sulfonylureas, insulinoma, anti-insulin antibodies</p>
<p class="bl"><span class="sbl">•</span> ↓ <b class="calibre4">glucose production:</b> hypopituitarism, adrenal insufficiency, glucagon deficiency, hepatic failure, renal failure, CHF, alcoholism, sepsis, severe malnutrition</p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">IGF-II:</b> non-islet tumor</p>
<p class="bl"><span class="sbl">•</span> Postprandial, esp. postgastrectomy or gastric bypass: excessive response to glc load</p>
<p class="bl"><span class="sbl">•</span> Low glc w/o sx can be normal</p>
<p class="h2a">Evaluation in nondiabetics <span class="s">(<i class="calibre3">JCEM</i> 2009;94:709)</span></p>
<p class="bl"><span class="sbl">•</span> If clinically ill: take measures to avoid recurrent hypoglycemia; ✔ BUN, Cr, LFTs, TFTs, prealbumin; IGF-I/IGF-II ratio when appropriate</p>
<p class="bl"><span class="sbl">•</span> If otherwise healthy: 72-h fast w/ monitored blood glc; stop for neuroglycopenic sx</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">At time of hypoglycemia:</i> insulin, C peptide (↑ w/ insulinoma and sulfonylureas, ↓ w/ exogenous insulin), β-OH-butyrate, sulfonylurea levels</p>
<p class="bl"><span class="sbl">•</span> At end of fast, give 1 mg glucagon IV and measure response of plasma glc before feeding</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Glucose tablets, paste, fruit juice are first-line Rx for Pts who can take POs</p>
<p class="bl"><span class="sbl">•</span> 25–50 g of D<sub class="calibre8">50</sub> IV; if no access, glucagon 0.5–1 mg IM or SC (side effect: N/V)</p>
<h2 class="ct"><a id="h98" class="calibre7"></a><a id="page_7-16" class="calibre7"></a><a href="part0002.html#rh108" class="calibre7">LIPID DISORDERS</a></h2>
<p class="h2a">Measurements</p>
<p class="bl"><span class="sbl">•</span> Lipoproteins = lipids (cholesteryl esters &amp; triglycerides) + phospholipids + proteins</p>
<p class="bl1">include: chylomicrons, VLDL, IDL, LDL, HDL, Lp(a)</p>
<p class="bl"><span class="sbl">•</span> Measure after 12-h fast; LDL typically calculated: LDL-C = TC – HDL-C – (TG/5) underestim. if TG &gt;400 or LDL-C &lt;70 mg/dL; ∴ directly measure LDL-C</p>
<p class="bl1">levels stable up to 24 h after ACS, then ↓ and may take 6 wk to return to nl</p>
<p class="bl"><span class="sbl">•</span> PEx clues: tendon xanthomas (eg, Achilles), imply LDL &gt;300 mg/dL; eruptive xanthomas on extensor surfaces imply TG &gt;1000 mg/dL; xanthelasma (yellowish streaks on eyelids)</p>
<p class="bl"><span class="sbl">•</span> Metabolic syndrome (≥3 of following): waist ≥40″ (♂) or ≥35″ (♀); TG ≥150; HDL &lt;40 mg/dL (♂) or &lt;50 mg/dL (♀); BP ≥130/85 mmHg; fasting glc ≥100 mg/dL <span class="s1r">(<i class="calibre3">Circ</i> 2009;120:1640)</span></p>
<p class="bl"><span class="sbl">•</span> Lp(a) = LDL particle bound to apo(a) via apoB; genetic variants a/w MI <span class="s1r">(<i class="calibre3">NEJM</i> 2009;361:2518)</span></p>
<p class="h2a">Dyslipidemias</p>
<p class="bl"><span class="sbl">•</span> 1°: <i class="calibre3">familial hyperchol.</i> (FH, 1:500): defective LDL receptor; ↑↑ chol, nl TG; ↑ CAD; <i class="calibre3">familial hypertrig.</i> (FHTG, 1:500): ↑ TG, ± ↑ chol, ↓ HDL, pancreatitis; and many others</p>
<p class="bl"><span class="sbl">•</span> 2°: DM (↑ TG, ↓ HDL), hypothyroidism (↑ LDL, ↑ TG), nephrotic syndrome (↑ LDL, ↑ TG), liver failure (↓ LDL), alcohol (↑ TG, ↑ HDL), thiazides (↑ LDL, ↑ TG), protease inhib (↑ TG)</p>
<p class="imagef"><img src="../images/00119.jpeg" alt="" class="calibre2"/></p>
<p class="fn">Resins ↓ LDL-C by ~20%, but not well tolerated; niacin ↑ HDL-C and ↓ TG &amp; LDL-C; no effect on CV outcomes.</p>
<p class="h2a">Treatment of LDL-C <span class="s">(<i class="calibre3">Lancet</i> 2014;384:607)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Statins:</b> every 1 mmol (39 mg/dL) ↓ LDL-C → 22% ↓ major vascular events (CV death, MI, stroke, revasc) in individuals w/ &amp; w/o CAD <span class="s1r">(<i class="calibre3">Lancet</i> 2010;376:1670)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ezetimibe:</b> ↓ major vascular events incl MI &amp; stroke when added to statin post-ACS, w/ magnitude of benefit consistent w/ LDL-statin relationship (IMPROVE-IT, <i class="calibre3">NEJM</i> 2015;372:2387)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">PCSK9 inhibitors:</b> ~60% ↓ LDL-C on top of statin, as monoRx, and in FH <span class="s1r">(<i class="calibre3">EHJ</i> 2014;35:2249)</span>; ↓ CV outcomes <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:1713 &amp; 2018;379:2097)</span></p>
<p class="h2a">Treatment of other lipid fractions <span class="s">(<i class="calibre3">Lancet</i> 2014;384:618 &amp; 626)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HDL-C:</b> low levels a/w ↑ risk of MI, but no clinical benefit shown by raising</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Triglycerides:</b> reasonable to treat levels &gt;500–1000 mg/dL w/ fibrates or Ω-3 FA to ↓ risk of pancreatitis; genetically-mediated lower levels a/w ↓ risk of CAD <span class="s1r">(<i class="calibre3">NEJM</i> 2014;371:22)</span>; modest benefit of fibrates on CV outcomes <span class="s1r">(<i class="calibre3">NEJM</i> 2010;362:1563 &amp; 2013;368:1800)</span>; high-dose Ω-3 FA (4 g/d of EPA) ↓ CV outcomes in Pts w/ ASCVD or DM <span class="s1r">(<i class="calibre3">NEJM</i> 2019:380:11)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lp(a):</b> consider ↓ to &lt;50 mg/dL in intermed- to high-risk Pts <span class="s1r">(<i class="calibre3">EHJ</i> 2010;31:2844)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre41"/>
<col class="calibre20"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabc"><b class="calibre4">2018 ACC/AHA Cholesterol Guidelines</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Circ</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">9;</span><span class="tfont">1</span><span class="tfont1">39:</span><span class="tfont">e</span><span class="tfont">1</span><span class="tfont">082</span><span class="tfont1">)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab"><b class="calibre4">Population</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Recommendation</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab">Very high-risk ASCVD<a id="st13" class="calibre1"></a><a href="part0012.html#sst13" class="calibre1">*</a></p></td>
<td class="bg0-b"><p class="tab">High-intensity statin; add EZE then PCSK9i if LDL-C ≥70</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab">Clinical ASCVD</p></td>
<td class="bg0-b"><p class="tab">High-intensity statin (? mod if &gt;75 y), add EZE if LDL-C ≥70</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab">LDL-C ≥190 mg/dL</p></td>
<td class="bg0-b"><p class="tab">High-intensity statin; add EZE or PCKS9i if LDL-C ≥100</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab">DM, age 40–75 y</p></td>
<td class="bg0-b"><p class="tab">High-intensity statin (? moderate if no CV RFs)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r" rowspan="4"><p class="tab">Age 40–75 y (and none of above); <i class="calibre3">calc 10-y risk</i></p></td>
<td class="bg0-br"><p class="tabc">≥20%</p></td>
<td class="bg0-b"><p class="tab">High-intensity statin</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">7.5%–&lt;20%</p></td>
<td class="bg0-b"><p class="tab">Moderate-intensity statin; if uncertain consider CAC</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">5–&lt;7.5%</p></td>
<td class="bg0-b"><p class="tab">Moderate-intensity statin reasonable</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">&lt;5%</p></td>
<td class="bg"><p class="tab">Emphasize lifestyle</p></td>
</tr>
</table>
<p class="tsr">ASCVD incl h/o ACS, stable angina, art. revasc, stroke, TIA, PAD. <a id="sst13" class="calibre1"></a><a href="part0012.html#st13" class="calibre1">*</a>Multiple major ASCVD events (MI, stroke, sx PAD) or 1 major event + multiple high-risk conditions (age ≥65, DM, HTN, CKD, smoking, FH, prior PCI/CABG). 10-y CV Risk Score: <a href="http://my.americanheart.org/cvriskcalculator" class="calibre1">http://my.americanheart.org/cvriskcalculator</a>. Additional risk factors to consider: LDL-C ≥160 mg/dl, met. synd.,CKD, FHx premature ASCVD, hsCRP ≥2 mg/l, Lp(a) ≥50 mg/dl, ABI &lt;0.9, high-risk ethnic groups.</p>
<p class="image1"><img src="../images/00120.jpeg" alt="" class="calibre2"/></p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0011.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0013.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
